ShareThis Page
Business Headlines

Biotech, energy shares jolt market

| Wednesday, April 6, 2016, 7:39 p.m.
Specialist Charles Boeddinghaus works with traders at the post that handles Allergan, on the floor of the New York Stock Exchange, Wednesday, April 6, 2016. The biggest U.S.-based drugmaker, Pfizer Inc., will stay put thanks to aggressive new Treasury Department rules that succeeded in blocking Pfizer from acquiring rival Allergan and moving to Ireland — at least on paper — to reduce its tax bill. (AP Photo/Richard Drew)
Specialist Charles Boeddinghaus works with traders at the post that handles Allergan, on the floor of the New York Stock Exchange, Wednesday, April 6, 2016. The biggest U.S.-based drugmaker, Pfizer Inc., will stay put thanks to aggressive new Treasury Department rules that succeeded in blocking Pfizer from acquiring rival Allergan and moving to Ireland — at least on paper — to reduce its tax bill. (AP Photo/Richard Drew)

NEW YORK — Stocks broke a two-day losing streak Wednesday as investors bought up drugmakers and other health care companies. Energy companies also jumped as the price of oil surged.

Biotech drug companies, which have been mired in a long slide, made their biggest gains in almost five years. That came after Pfizer, one of the largest pharmaceutical companies in the world, gave up on a plan to buy Botox maker Allergan for $160 billion and investors wondered if it will look elsewhere.

The gains were only enough to wipe out most of the market's losses from a day earlier. Stocks wavered in recent weeks as investors wait for quarterly earnings to start pouring in, and many are bracing for another shaky quarter.

Jack Ablin, chief investment officer of BMO Private Bank, said it's going to be another weak earnings period, and the only way stocks will trade much higher is if companies are able to give optimistic projections for the rest of the year.

“Without an improvement in earnings or a projection of earnings growth, our outlook is kind of tapped out,” he said.

The Dow Jones industrial average gained 112.73 points, or 0.6 percent, to 17,716.05. The Standard & Poor's 500 index rose 21.49 points, or 1.1 percent, to 2,066.66. The Nasdaq composite index picked up 76.78 points, or 1.6 percent, to 4,920.72.

Biotechnology companies climbed on news of the canceled Pfizer-Allergan deal. Celgene, which makes treatments for cancer, gained $6.10, or 6 percent, to $108.22. Vertex Pharmaceuticals rose $7.15, or 8.5 percent, to $91.31.

Biotech stocks are facing pressure from legislators over the price of their drugs, and investors fear that their ability to raise prices will be impeded.

Energy companies gained ground as benchmark U.S. crude rose. Chevron picked up $2.17, or 2.3 percent, to $94.84, and Exxon Mobil added $1.10, or 1.3 percent, to $83.31. Hess rose $2.74, or 5.3 percent, to $54.

While the pace of company earnings will climb next week, a few companies made big moves Wednesday after they disclosed their results. Constellation Brands, the owner of Corona, Negra Modelo and Pacifico beers, reported solid quarterly results and raised its profit forecasts for the year. Its stock rose $8.98, or 5.9 percent, to $160.34.

Electronic payment processing company Global Payments gained $5.71, or 8.8 percent, to $70.86 after it posted strong quarterly results.

Lighting maker Cree said its sales will fall far short of expectations because of new product delays and software problems. The company said it may take a loss in the third quarter. Its stock lost $4.24, or 14.6 percent, to $24.81.

Ablin of BMO Private Bank said he thinks companies with a long history of maintaining or raising their dividends will do the best in the weeks and months to come. Telecommunications companies pay some of the biggest dividends on the market, and they slumped Wednesday as AT&T and Verizon prepared to pay out billions of dollars in dividends.

Harley-Davidson took the biggest loss on the S&P 500, as it gave up $3.50, or 7 percent, to $46.34. Analyst John Tomlinson of ITG Investment Research said he thinks the motorcycle company lost market share over the first three months of this year, and said he thinks its retail sales in the United States will drop in the first quarter.

TribLIVE commenting policy

You are solely responsible for your comments and by using TribLive.com you agree to our Terms of Service.

We moderate comments. Our goal is to provide substantive commentary for a general readership. By screening submissions, we provide a space where readers can share intelligent and informed commentary that enhances the quality of our news and information.

While most comments will be posted if they are on-topic and not abusive, moderating decisions are subjective. We will make them as carefully and consistently as we can. Because of the volume of reader comments, we cannot review individual moderation decisions with readers.

We value thoughtful comments representing a range of views that make their point quickly and politely. We make an effort to protect discussions from repeated comments either by the same reader or different readers

We follow the same standards for taste as the daily newspaper. A few things we won't tolerate: personal attacks, obscenity, vulgarity, profanity (including expletives and letters followed by dashes), commercial promotion, impersonations, incoherence, proselytizing and SHOUTING. Don't include URLs to Web sites.

We do not edit comments. They are either approved or deleted. We reserve the right to edit a comment that is quoted or excerpted in an article. In this case, we may fix spelling and punctuation.

We welcome strong opinions and criticism of our work, but we don't want comments to become bogged down with discussions of our policies and we will moderate accordingly.

We appreciate it when readers and people quoted in articles or blog posts point out errors of fact or emphasis and will investigate all assertions. But these suggestions should be sent via e-mail. To avoid distracting other readers, we won't publish comments that suggest a correction. Instead, corrections will be made in a blog post or in an article.

click me